Future anti-inflammatory metabolic and cardiovascular management of Type 2 diabetes mellitus

Bibliography

• LAIGHT DW: Therapeutic approaches to the management of dysmetabolic cardiovascular disease. Expert Opin. Then Patents (2002) 12:615–620.
   Web of Science ®Google Scholar
• GURNELL M, SAVAGE DB, CHATTERJEE KK et al.: The metabolic syndrome: peroxisome proliferator-activated receptor-7 and its therapeutic modulation. j Clin. Endocrinol Metab. (2003) 88:2412–2421.
   PubMed Web of Science ®Google Scholar
• LAIGHT DW, CARRIER MJ, ANGGARD EE: Antioxidants, diabetes and endothelial dysfunction. Cardiovasc. Res. (2000) 47:457–464.
   PubMed Web of Science ®Google Scholar
• LAIGHT DW, CARRIER MJ, ANGGARD EE: Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab. Res. Rev. (1999) 15:274–282.
   PubMed Web of Science ®Google Scholar
• SOWERS JR: Update on the cardiometabolic syndrome. Diabetes (2001) 4:17–23.
   Google Scholar
• ABATE N: Obesity and cardiovascular disease. Pathogenic role of the metabolic syndrome and therapeutic implications. 1. Diabetes Comp. (2000) 14:154–174.
   Google Scholar
• HAFFNER SM: The prediabetic problem: development of non-insulin-dependent diabetes mellitus and related abnormalities. " Diabetes Comp. (1997) 11:69–76.
   PubMed Web of Science ®Google Scholar
• MARKS JB, RASKIN P: Cardiovascular risk in diabetes - a brief review.' Diabetes Comp. (2000) 14:108–115.
   PubMed Web of Science ®Google Scholar
• HAFFNER SM: Prediabetes, insulin resistance, inflammation and CVD risk. Diabetes Res. Clin. Pract. (2003) 61:S9–S18.
   Google Scholar
• DANDONA P, ALJADA A, CHAUDHURI A, BANDYOPADHYAY A: The potential influence of inflammation and insulin on the pathogenesis and treatment of atheroslcerosis-related complications in Type 2 diabetes. " Clin. Endocrinol Metab. (2003) 88:2422–2429.
   PubMedGoogle Scholar
• WILDS, BYRNE C: Prevention of Type 2 diabetes and associated cardiovascular disease. Cardiabetes (2001) 1:20–25.
   Google Scholar
• NO AUTHORS LISTED: Effects of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes mellitus (UK Prospective Diabetes Study (UKPDS) group 34). Lancet (1998) 356:854–865.
   Google Scholar
• LAIGHT DW: Therapeutic approaches to insulin resistance. Expert Opin. Then Patents (2000) 10:1703–1709.
   Web of Science ®Google Scholar
• BIONDI-ZOCCAI GGL, ABBATE A, LIUZZO G et al.: Atherosclerosis, inflammation and diabetes. Am. J. Cardiol (2003) 41:1071–1077.
   Google Scholar
• PLUTZKY J, VIBERTI G, HAFFNER S: Atherosclerosis in Type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. " Diabetes Comp. (2002) 16:401–415.
   PubMed Web of Science ®Google Scholar
• GREENBERG AS: The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in Type 2 diabetes with particular focus on the emerging role of the thiazolidinediones. " Diabetes Comp. (2003) 17:218–228.
   PubMed Web of Science ®Google Scholar
• DAS UN: Is metabolic syndrome X an inflammatory condition? Exp. Biol. Med. (2002) 227:989–997.
   Google Scholar
• DUNCAN BB, SCHMIDT MI: Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paulo Med. J. (2001) 119:122–127.
   PubMedGoogle Scholar
• SYED MA, BARINAS-MITCHELL E, PIETROPAOLO SL et al.: Is Type 2 diabetes a chronic inflammatory/autoimmune disease? Diab. Num. Metab. (2002) 15:68–83.
   Google Scholar
• PICKUP JC, CROOK MA: Is Type II diabetes mellitus a disease of the innate immune system? Diabetologia (1998) 41:1241–1248.
   PubMed Web of Science ®Google Scholar
• HAYDEN JM, REAVEN PD: Cardiovascular disease in diabetes mellitus Type 2: a potential role for novel cardiovascular risk factors. Curt: Opin. Lipidol (2000) 11:519–528.
   Google Scholar
• THORAND B, LOWEL H, SCHNEIDER A et al.: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men. Arch. Intern. Med. (2003) 163:93–99.
   PubMed Web of Science ®Google Scholar
• CHAN JC, CHEUNG JC, STEHOUWER CD et al.: The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the metabolic syndrome - an analysis by structural equation modelling. Int. J. Obesity(2002) 26:994–1008.
   PubMed Web of Science ®Google Scholar
• PRADHAN AD, RIDKER PM: Do atheroslcerosis and Type 2 diabetes share a common inflammatory basis? Eur: Heart J. (2002) 23:831–834.
   Google Scholar
• STEHOUWER CD, GALL MA, TWISK JW et al.: Increased urinary albumin excretion, endothelial dysfunction and chronic low-grade inflammation in Type 2 diabetes. Diabetes (2002) 51:1157–1165.
   PubMed Web of Science ®Google Scholar
• SHURTZ-SWIRSKI R, SELA S, HERSKOVITS AT et al.: Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in Type 2 diabetic patients. Diabetes Care (2001) 24:104–110.
   PubMed Web of Science ®Google Scholar
• LINDSAY RS, KRAKOFF J, HANSON RL, BENNETT PH, KNOWLER WC: 7-globulin levels predict Type 2 diabetes in the Pima Indian population. Diabetes (2001) 50: 1598-1603.
   Google Scholar
• VOZAROVA B, WEYER C, LINDSAY RS, PRATLEY RE, BOGARDUS C, TATARANNI PA: High white cell count is associated with worsening of insulin sensitivity and predicts development of Type 2 diabetes. Diabetes (2002) 51:455–461.
   PubMed Web of Science ®Google Scholar
• FESTA A, D'AGOSTINO R, TRACY RP et al.: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of Type 2 diabetes. Diabetes (2002) 51:1131–1137.
   Google Scholar
• LEINONEN E, HURT-CAMEJO E, WIKLUND O, HULTEN LM, HIUKKA A, TASKINEN MR: Insulin resistance and adiposity correlate with acute-phase reaction and soluble adhesion molecules in Type 2 diabetes. Atherosclerosis (2003) 166:387–394.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, BURING JE, COOK NR,RIFAI N: C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events. Circulation (2003) 107:391–397.
   PubMed Web of Science ®Google Scholar
• ENGSTROM G, STAVENOW L, HEDBLAD B et al: Inflammation-sensitive plasma proteins, diabetes and mortality and incidence of myocardial infarction and stroke. Diabetes (2003) 52:442–447.
   PubMed Web of Science ®Google Scholar
• DESSEIN PH, JOFFE BI, STANWIX AE: Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res. (2002) 4:R12.
   Google Scholar
• DAS UN: Is obesity an inflammatory condition? Nutrition (2001) 17:953–966.
   PubMed Web of Science ®Google Scholar
• GRIMBLE RF: Inflammatory status and insulin resistance. Carr: Opin. Clin. Nutr: Metab. Care (2002) 5:551–559.
   PubMed Web of Science ®Google Scholar
• BEHRENDT D, GANZ P: Endothelial function: from vascular biology to clinical applications. Am. Cardiol (2002) 90:40L–48L.
   Google Scholar
• VICENT D, IILANY J, KONDO T et al: The role of endothelial cell signalling in the regulation of vascular tone and insulin resistance. I Clin. Invest. (2003) 111:1373–1380.
   PubMedGoogle Scholar
• LI X, KOLLTVEIT KM, TRONSTAD L, OLSEN I: Systemic diseases caused by oral infection. Clin. Microbial. Rev. (2000) 13:547–558.
   PubMed Web of Science ®Google Scholar
• GLURICH I, GROSSI S, ALBINI B et al.: Systemic inflammation in cardiovascular and periodontal disease: comparative study. Clin. Diagnostic Lab. Immunol (2002) 9:425–432.
   PubMedGoogle Scholar
• GROSSI SG, GENCO RJ: Periodontal disease and diabetes mellitus: a two-way relationship. Ann. Periodontol (1998) 3:51–61.
   PubMedGoogle Scholar
• ALJADA A: Endothelium, inflammation and diabetes. Metab. Syndrome Rel. Disorders (2003) 1:3–21.
   Google Scholar
• ROSENSON RS, KONIG W: Utility of inflammatory markers in the management of coronary artery disease. Am. Cardiol (2003) 92:10i–18i.
   Google Scholar
• HUNDAL RS, PETERSEN KF, MAYERSON AB et al.: Mechanism by which high-dose aspirin improves glucose metabolism in Type 2 diabetes. Clin. Invest. (2002) 109:1321–1326.
   Google Scholar
• KIM JK, YOON-JUNG K, FILLMORE JJ et al.: Prevention of fat-induced insulin resistance by salicylate. Clin. Invest. (2001) 108:437–446.
   Google Scholar
• MANCINI GBJ: Emerging role of angiotensin II Type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. Can. J. Cardiol (2002) 18:1309–1316.
   Google Scholar
• HOLM T, ANDREASSEN AK, UELAND T et al.: Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am. J. Cardiol (2001) 87:815–818.
   PubMed Web of Science ®Google Scholar
• BRASIER AR, RECINOS A III, ELEDRISI MS: Vascular inflammation and the renin-angiotensin system. Arteriosclec Thromb. Vase. Biol. (2002) 22:1257–1266.
   PubMed Web of Science ®Google Scholar
• MAGSINO CH, HAM OUDA W, BAPNA V et al.: Nadolol inhibits reactive oxygen species generation by leukocytes and linoleic acid oxidation. Am. Cardiol (2000) 86:443–448.
   Google Scholar
• DANDONA P, KUMAR V, ALJADA A et al.: Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor lcB, in mononuclear cells of normal subjects: evidence of an anti-inflammatory action. J. Clin. Endocrinol Metab. (2003) 88:4496–4501.
   PubMed Web of Science ®Google Scholar
• DANDONA P, KARNE R, GHANIM H, HAM OUDA W, ALJADA A, MAGSINO CH Jr: Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation (2000) 101:122–124.
   PubMed Web of Science ®Google Scholar
• MIKKOLA TS, CLARKSON TB: Oestrogen replacement therapy, atherosclerosis and vascular function. Cardiovasc. Res. (2002) 53:605–619.
   PubMed Web of Science ®Google Scholar
• MAGSINO CH Jr, HAMOUDA W, GHANIM H, BROWNE R, ALJADA A, DANDONA P: Effect of triiodothyronine on reactive oxygen species generation by leukocytes, indices of oxidative damage and antioxidant reserve. Metabolism (2000) 49:799–803.
   Google Scholar
• LAIGHT DW: Nitric oxide therapy for cardiovascular disease. Expert Opin. Then Patents (2001) 11:999–1005.
   Web of Science ®Google Scholar
• VIBERTI GC: Rosiglitazone: potential beneficial impact on cardiovascular disease. Int. I Clin. Pract. (2003) 57:128–134.
   Google Scholar
• FRUCHART JC, STAELS B, DURIEZ P: PPARS, metabolic disease and atheroslcerosis. Pharmacol Res. (2001) 44:345–352.
   PubMed Web of Science ®Google Scholar
• GHANIM H, GARG R, ALJADA A et al.: Suppression of nuclear factor-KB and stimulation of inhibitor lcB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherogenic effect in the obese. Clin. Endocrinol Metab. (2001) 86:1306–1312.
   Google Scholar
• ZIMMET P: Addressing the insulin resistance syndrome - a role for thiazolidinediones. Trends Cardiovasc. Med. (2002) 12:354–362.
   PubMed Web of Science ®Google Scholar
• WAKINO S, LAW RE, HSUEH WA: Vascular protective effects by activation of nuclear receptor PPARy. Diabetes Comp. (2002) 16:46–49.
   Google Scholar
• RAM VI: Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation. Frog. Drug Res. (2003) 60:94–132.
   Google Scholar
• ASNANI S, THEUMA P, FONSECA VA: PPARy agonists and vascular risk factors: potential effects on cardiovascular disease. Metab. Syndrome Rel. Disorders (2003) 1:23–53.
   PubMed Web of Science ®Google Scholar
• LEBOVITZ HE: Rationale for and role of thiazolidinediones in Type 2 diabetes mellitus. Am. J. Cardiol (2002) 90:34G–41G.
   Google Scholar
• MARTENS FM, VISSEREN FL, LEMAY J et al.: Metabolic and additional vascular effects of thiazolidinediones. Drugs (2002) 62:1463–1480.
   PubMed Web of Science ®Google Scholar
• OMI H, OKAYAMA N, SHIMIZU M et al.: Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells- effect of antidiabetic medicines. Diabetes Comp. (2002) 16:201–208.
   PubMed Web of Science ®Google Scholar
• DANDONA P, ALJADA A: A rational approach to pathogenesis and treatment of Type 2 diabetes mellitus, insulin resistance, inflammation and atheroslcerosis. Am. Cardiol. (2002) 90:27G–33G.
   Google Scholar
• DANDONA P, ALJADA A, MOHANTY P et at Insulin inhibits intranuclear nuclear factor lcB and stimulates IlcB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? Clin. Endocrinol. Metab. (2001) 86:3257–3265.
   Google Scholar
• BARZILAYJI, FREEDLAND ES: Inflammation and its relationship to insulin resistance, Type 2 diabetes mellitus and endothelial dysfunction. Metab. Syndrome Rel. Disorders. (2003) 1:55–67.
   Google Scholar
• SCOTT CL: Diagnosis, prevention and intervention for the metabolic syndrome. Am. Cardiol (2003) 92:35i–42i.
   Google Scholar
• KONIG W: Insulin resistance, heart disease and inflammation. Int. Clin. Pharmacol (2002) S132:23–31.
   Google Scholar
• MCFARLANE SI, KUMAR A, SOWERS JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am.j Cardiol. (2003) 91:30H–37H.
   Google Scholar
• FREEMAN DJ, NORRIE J, SATTAR N et al.: Pravastatin and the development of diabetes mellitus. Circulation (2001) 103:357–362.
   PubMed Web of Science ®Google Scholar
• SOWERS JR: Effects of statins on the vasculature: implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am. J. Cardiol (2003) 91:14B–22B.
   Google Scholar
• BUCHANAN TA, XIANG AH, PETERS RK et al.: Preservation of pancreatic I3-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes (2002) 51:2796–2803.
   PubMed Web of Science ®Google Scholar
• CAMPBELL IW: Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in Type 2 diabetes mellitus? Drugs (2000) 60:1017–1028.
   PubMed Web of Science ®Google Scholar
• GUNNETT CA, HEISTAD DD, FARACI FM: Interleukin-10 protects nitric oxide-dependent relaxation during diabetes. Diabetes (2002) 51: 1931-1937.
   Google Scholar
• ASADULLAH K, STERRY W, VOLK HD:Interleukin-10 therapy - a new approach. Pharmacol Rev (2003) 55:241–269.
   PubMed Web of Science ®Google Scholar
• NISHIMURA F, MURAYAMA Y: Periodontal inflammation and insulin resistance - lessons from obesity. J. Dent. Res. (2001) 80:1690–1694.
   Google Scholar
• STIER CT Jr: Eplerenone: a selective aldosterone blocker. Cardiovasc. Drug Rev (2003) 21:169–184.
   Google Scholar
• LAIGHT DW, DESAI KM, GOPAUL NK, ANGGARD EE, CARRIER MJ: Pro-oxidant challenge in vivo provokes the onset of NIDDM in the insulin resistant obese Zucker rat. Br: J. Pharmacol (1999) 128:269–271.
   PubMed Web of Science ®Google Scholar
• LAIGHT DW: Organic nitrate-induced oxidant stress and cardiovascular therapy. Expert Opin. Then Patents (2003) 13:1–6.
   Google Scholar
• http://www.update-software.com BELCH JJF: The Prevention Of Progression of Asymptomatic Diabetic Arterial Desease (POPADAD) study, a multicentre study. Accessed 27 August 2003. The goal of this study was to determine whether or not aspirin and antioxidant therapy can reduce the incidence of vascular events in diabetic individuals.
   Google Scholar
• http://www.update-software.com DAVID M: DREAM trial: diabetes reduction assessment with ramipril and rosiglitazone medication trial. Accessed 27 August 2003. The goal of this study was to determine whether ramipril or rosiglitazone reduces incident diabetes in subjects at risk.
   Google Scholar
• www.update-software.com JOHNSTON D: Rosiglitazone and plaque study: a 12-month randomised, double-blind, placebo-controlled, magnetic resonance imaging study to evaluate the subjects with T2DM and co-existing vascular disease or hypertension. Accessed 27 August 2003. The goal of this study was to examine the effect of rosiglitazone on carotid atheroma and cardiovascular risk factors in T2DM.
   Google Scholar
• http://www.update-software.com PAGE MD: PROATIVE: prospective pioglitazone clinical trial in macrovascular events. Accessed 27 August 2003. The goal of this study was to demonstrate that pioglitazone reduces mortality and macrovascular morbidity in high-risk patients with T2DM.
   Google Scholar
• http://www.update-software.com MACLAREN N: A clinical trial to prevent the complications of insulin resistance (including Type 2 diabetes). Accessed 27 August 2003. The goal of this study was to treat emergent insulin resistance and clinical manifestations in childhood and prevent progression to T2DM. Interventions include metformin plus pioglitazone or rosiglitazone.
   Google Scholar